Common use of Purchase Price for Termination of Biologic Products Commercialization Agreement Clause in Contracts

Purchase Price for Termination of Biologic Products Commercialization Agreement. The purchase price for the Termination of the Biologic Products Commercialization Agreement is Five Million Five Hundred Thousand Dollars ($5,500,000) (the “Purchase Price”). The Purchase Price shall be paid by Biovest delivering to Accentia at Closing Five Million (5,000,000) shares of Biovest fully paid and non-assessable common stock, par value $0.01, valued at $1.10 per share.

Appears in 4 contracts

Samples: Royalty Agreement, Royalty Agreement (Accentia Biopharmaceuticals Inc), Royalty Agreement (Biovest International Inc)

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!